Clinical Updates & Insights

Share
Print

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
143 Clinical Updates found
C. Jillian Tsai
MSK Finds De-escalation of Radiotherapy Safely Limits Side Effects for HPV-Associated Oropharyngeal Cancer

A study by Memorial Sloan Kettering (MSK) recently published in JAMA Oncology showed that radiation dose to the elective regions can be safely de-escalated for patients with human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) who received concurrent chemotherapy.
Vinod Balachandran, MD
Custom mRNA Vaccines for Pancreatic Cancer

Cancer vaccines that use messenger RNA (mRNA) technology are an exciting new approach to develop immunotherapies for cancers with poor prognoses, such as pancreatic cancer.
MSK's team of experts discussing advanced therapies available to treat acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia.
Promising Results in Phase 1 Study of Novel Menin Inhibitor for Aggressive Leukemia

The oral menin inhibitor SNDX-5613 (Syndax Pharmaceuticals) demonstrated promising antileukemic activity and an acceptable safety profile in patients w...
2021 in Review: 10 Important Clinical Advances in Cancer at MSK

MSK Chief of the Lymphoma Service Gilles Salles Presents Promising New Treatment for Patients with Diffuse Large B-Cell Lymphoma

Shape-Sensing Robotic-Assisted Bronchoscopy May Improve Diagnostic Efficiency, Shorten Time to Treatment for Patients with Malignant Lung Lesions

Shape-sensing robotic-assisted bronchoscopy (ssRAB) may improve the diagnostic yield of suspicious pulmonary lesions while providing an excellent saf...
The timing and order of treatment modalities to address brain metastases is complex. MSK’s multidisciplinary brain metastasis experts create a customized treatment plan for each patient, ensuring multimodality treatments are delivered in the best order, as quickly as possible, for the greatest benefits.
Multimodality Care Is Improving Survival for Patients with Melanoma Brain Metastasis

Overall survival (OS) for patients with melanoma brain metastasis treated at Memorial Sloan Kettering Cancer Center has increased significantly over the past five years, up to 13 months, according to our research published recently in Cancer.
A Milestone for Precision Oncology: FDA Gives Green Light to MSK’s Genetic Database

OncoKB, a database developed and maintained by investigators at MSK, helps match patients with targeted therapies based on the mutations found in their tumors.
ASTRO 2021: New Study from Memorial Sloan Kettering Cancer Center Finds Targeted Radiation Beneficial in Cases of Advanced Lung Cancer

By C. Jillian Tsai, MD, PhD
Doctor and patient at MSK’s Multidisciplinary Brain Metastasis Clinic
Shorter time to stereotactic radiosurgery after brain metastases resection improves patient outcomes

Local control rates and overall survival (OS) were significantly higher for patients with brain metastases treated with adjuvant stereotactic radiosurgery (SRS) within two months of resection, compared to longer time intervals, according to our new study published recently in Neuro-Oncology Practice.